Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss

Stock Track05-06

Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.

The sharp decline is attributed to the company reporting a significant quarterly loss that missed analyst expectations. BioCryst posted a Q1 net loss of $2.98 per share, starkly contrasting with the FactSet consensus estimate for a profit of $0.04 per share. Total revenue for the quarter was $156.4 million, which exceeded the expected $151.1 million, but was overshadowed by the substantial bottom-line miss.

The widened net loss of $721.8 million included a $697.8 million non-cash acquired in-process R&D charge related to the Astria Therapeutics acquisition. Despite maintaining its full-year revenue guidance for its flagship drug ORLADEYO, the surprise quarterly loss prompted negative investor sentiment in pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176521691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176521691","market":"nz","top_or_hot":-1,"title":"Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss","media":"Stock Track","content":"<p>Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The sharp decline is attributed to the company reporting a significant quarterly loss that missed analyst expectations. BioCryst posted a Q1 net loss of $2.98 per share, starkly contrasting with the FactSet consensus estimate for a profit of $0.04 per share. Total revenue for the quarter was $156.4 million, which exceeded the expected $151.1 million, but was overshadowed by the substantial bottom-line miss.</p><p>The widened net loss of $721.8 million included a $697.8 million non-cash acquired in-process R&D charge related to the Astria Therapeutics acquisition. Despite maintaining its full-year revenue guidance for its flagship drug ORLADEYO, the surprise quarterly loss prompted negative investor sentiment in pre-market trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The sharp decline is attributed to the company reporting a significant quarterly loss that missed analyst expectations. BioCryst posted a Q1 net loss of $2.98 per share, starkly contrasting with the FactSet consensus estimate for a profit of $0.04 per share. Total revenue for the quarter was $156.4 million, which exceeded the expected $151.1 million, but was overshadowed by the substantial bottom-line miss.</p><p>The widened net loss of $721.8 million included a $697.8 million non-cash acquired in-process R&D charge related to the Astria Therapeutics acquisition. Despite maintaining its full-year revenue guidance for its flagship drug ORLADEYO, the surprise quarterly loss prompted negative investor sentiment in pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1176521691","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176521691","pubTimestamp":1778071702,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.The sharp decline is attributed to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"个股追踪|BioCryst Pharmaceuticals季度意外亏损盘前暴跌6.98%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.The sharp decline is attributed to the company reporting a significant quarterly loss that missed analyst expectations. BioCryst posted a Q1 net loss of $2.98 per share, starkly contrasting with the FactSet consensus estimate for a profit of $0.04 per share. Total revenue for the quarter was $156.4 million, which exceeded the expected $151.1 million, but was overshadowed by the substantial bottom-line miss.The widened net loss of $721.8 million included a $697.8 million non-cash acquired in-process R&D charge related to the Astria Therapeutics acquisition. Despite maintaining its full-year revenue guidance for its flagship drug ORLADEYO, the surprise quarterly loss prompted negative investor sentiment in pre-market trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176521691","isCrawlerRequest":true}